Captrust Financial Advisors Boosts Position in AbbVie Inc. $ABBV

Key Points

• Captrust Financial Advisors raised its AbbVie stake by 2.7% in Q3, buying 38,309 shares to hold 1,474,836 shares worth about $341.5 million (≈0.08% ownership).
• Insider selling was notable: EVP Perry Siatis sold 22,381 shares (~$5.15M) and SVP David Purdue sold 5,230 shares (~$1.22M), while hedge funds and other institutions own roughly 70.23% of the stock.
• AbbVie beat quarterly EPS and revenue estimates, issued FY2026 guidance of $14.37–$14.57 EPS, has a consensus analyst rating of "Moderate Buy" (target ~$253.15), and declared a $1.73 quarterly dividend (≈3.1% yield).

Captrust Financial Advisors boosted its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 2.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,474,836 shares of the company's stock after purchasing an additional 38,309 shares during the quarter. Captrust Financial Advisors owned about 0.08% of AbbVie worth $341,484,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in ABBV. Ellenbecker Investment Group boosted its holdings in shares of AbbVie by 0.8% in the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company's stock valued at $1,235,000 after buying an additional 44 shares in the last quarter. Security National Bank of Sioux City Iowa IA raised its stake in AbbVie by 0.3% during the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company's stock worth $3,562,000 after acquiring an additional 45 shares in the last quarter. Matthew Goff Investment Advisor LLC lifted its position in AbbVie by 0.3% in the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company's stock valued at $4,066,000 after acquiring an additional 45 shares during the last quarter. Centennial Wealth Advisory LLC boosted its stake in AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company's stock valued at $484,000 after acquiring an additional 45 shares in the last quarter. Finally, Willner & Heller LLC boosted its stake in AbbVie by 0.6% in the third quarter. Willner & Heller LLC now owns 7,596 shares of the company's stock valued at $1,759,000 after acquiring an additional 46 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the firm's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.08% of the company's stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Alloy Therapeutics signed a multi‑year agreement with AbbVie to develop a next‑generation antibody discovery platform; Alloy will receive an upfront payment plus milestones, which can accelerate discovery of hard‑to‑drug targets and provide non‑dilutive near‑term cash. Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
• Positive Sentiment: William Blair reiterated confidence in AbbVie’s growth prospects tied to obesity treatment progress after positive Phase 1 results — this underscores potential upside from a new high‑growth therapeutic area beyond core franchises. William Blair Asserts AbbVie Inc. (ABBV) Growth Prospects on Obesity Treatment Opportunities
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) launched a Skin Quality Index to standardize patient/provider conversations in aesthetics — a marketing and product‑positioning move that can support elective‑procedure demand and cross‑sell across Allergan’s portfolio. AbbVie’s Skin Quality Index Aims To Shape Aesthetics Growth Narrative
• Positive Sentiment: Notable institutional interest: Billionaire Ken Fisher’s fund has included AbbVie among its notable 2026 moves, signaling confidence from an established investor and potential buying support. AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock
• Neutral Sentiment: Zacks and other analysts highlight AbbVie as a strong value stock based on valuation metrics and steady cash flows — useful context for longer‑term investors but not an immediate price catalyst. Here's Why AbbVie (ABBV) is a Strong Value Stock
• Neutral Sentiment: A U.S. appeals court revived a whistleblower lawsuit alleging overcharging on drugs for low‑income patients against several large drugmakers, creating a sector‑level legal overhang; it’s unclear from published reports whether AbbVie is a named defendant, but the ruling increases regulatory/legal risk for big pharma generally. Big drugmakers must face US overcharge claims on medications for low-income patients
• Negative Sentiment: Technical pressure — several market writeups note ABBV has slipped below its 50‑day simple moving average, signaling short‑term momentum weakness and prompting traders to take profits or wait for a dip to re‑enter. AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. HSBC upgraded AbbVie from a "hold" rating to a "buy" rating and lifted their target price for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. William Blair restated an "outperform" rating on shares of AbbVie in a research note on Monday, March 9th. UBS Group cut their price target on AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a research report on Thursday, February 5th. Berenberg Bank set a $275.00 price objective on AbbVie in a research note on Tuesday, January 20th. Finally, Barclays started coverage on AbbVie in a report on Thursday, February 19th. They issued an "overweight" rating and a $275.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, AbbVie currently has a consensus rating of "Moderate Buy" and a consensus price target of $253.15.

AbbVie Stock Down 0.7%

Shares of ABBV stock opened at $219.96 on Wednesday. The stock's 50-day moving average price is $224.27 and its 200 day moving average price is $224.95. The stock has a market capitalization of $388.92 billion, a PE ratio of 93.20, a price-to-earnings-growth ratio of 0.77 and a beta of 0.34. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company's revenue was up 10.0% on a year-over-year basis. During the same period last year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.